Net Worth Advisory Group’s Novo Nordisk NVO Stock Holding History

Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake
Trade Value Portfolio Weight Portfolio Position
2026
Q2
$298K Sell
6,216
-853
-12% -$36.6K 0.08% 287
2026
Q1
$260K Buy
7,069
+2,628
+59% +$125K 0.05% 347
2025
Q4
$226K Sell
4,441
-1,816
-29% -$92.9K 0.05% 405
2025
Q3
$347K Sell
6,257
-1,128
-15% -$66K 0.1% 230
2025
Q2
$510K Buy
7,385
+1,605
+28% +$109K 0.11% 191
2025
Q1
$401K Sell
5,780
-31
-0.5% -$2.56K 0.13% 188
2024
Q4
$500K Sell
5,811
-243
-4% -$26.3K 0.15% 175
2024
Q3
$721K Buy
+6,054
New +$807K 0.21% 113

Other funds holding NVO

Net Worth Advisory Group's NVO Position: Q2 2026 in Review

Net Worth Advisory Group reduced its Novo Nordisk (NVO) stake by 12% in Q2 2026, selling an estimated $36.6K and leaving 6,216 shares worth $298K. The position accounts for 0.08% of the portfolio, ranked #287.

Net Worth Advisory Group first reported a position in NVO in Q3 2024 and has held it in 8 quarters since. The position peaked at $721K in Q3 2024. 269 funds tracked by Wall St. Rank hold NVO as of Q2 2026.

  • Net Worth Advisory Group held 6,216 shares of Novo Nordisk worth $298K as of Q2 2026.
  • Net Worth Advisory Group sold 853 Novo Nordisk shares in Q2 2026, an estimated $36.6K.
  • Novo Nordisk made up 0.08% of Net Worth Advisory Group's portfolio in Q2 2026, its #287 holding.
  • Net Worth Advisory Group first reported a position in Novo Nordisk in Q3 2024 and has held it in 8 quarters since.
  • Net Worth Advisory Group's Novo Nordisk position peaked at $721K in Q3 2024.
  • 269 funds tracked by Wall St. Rank held Novo Nordisk as of Q2 2026.

Based on Net Worth Advisory Group's 13F filing for Q2 2026, filed 14 Jul 2026.